ALXO — ALX ONCOLOGY HOLDINGS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1810182 ·
Last close
$1.31
Market Cap
$181.14M
52W High
$2.66
52W Low
$1.05
ADV30
890,880
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -18,271,000 | -17,971,000 | 160,820,000 | 22,687,000 | 24,633,000 |
| Mar 2026 | 0 | — | -18,966,000 | -17,927,000 | 178,328,000 | 32,284,000 | 26,981,000 |
| Dec 2025 | 0 | — | -23,021,000 | -22,848,000 | 59,046,000 | 16,373,000 | 33,065,000 |
| Sep 2025 | 0 | — | -22,532,000 | -22,144,000 | 82,723,000 | 23,442,000 | 37,923,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-70,778,000
Investing CF
$-65,888,000
Financing CF
$140,251,000
CapEx
$-172,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.13
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-758,715,000
Inventory
—
Receivables
$1,171,000
ST Investments
$115,542,000
EBIT TTM
$-79,483,000
Pretax Income TTM
$-80,890,000
Interest Exp TTM
$1,407,000
Analysts
5
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -100,846,000 | -101,695,000 | 59,046,000 | 33,065,000 | 25,981,000 | -84,142,000 |
| Dec 2024 | 0 | -142,467,000 | -134,850,000 | 147,775,000 | 34,157,000 | 113,618,000 | -121,912,000 |
| Dec 2023 | 0 | -170,278,000 | -160,805,000 | 242,553,000 | 52,841,000 | 189,712,000 | -130,364,000 |
| Dec 2022 | 0 | -127,436,000 | -123,482,000 | 306,489,000 | 43,025,000 | 263,464,000 | -89,223,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.54
Max Pain — expiry 2027-01-15
max pain strike: $1.00 · spot: $1.34 · call oi: 997 · put oi: 28
Expected Move to 2027-01-15:
±$0.78
(58.05%) —
implied range
$0.56 –
$2.11
· ATM straddle on $1.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ORGO | Organogenesis Holdings Inc. | $181.43M | $1.41 | — |
| PEPG | PepGen Inc. | $179.15M | $2.59 | — |
| ANTX | AN2 Therapeutics, Inc. | $184.15M | $4.88 | — |
| MSLE | Satellos Bioscience Inc. | $184.58M | $8.70 | — |
| BCYC | BICYCLE THERAPEUTICS PLC | $186.29M | $3.68 | — |
News headlines (Yahoo Finance, 1h cache)
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
2026-09-28 12:00 · Yahoo
ALX Oncology to Present at Upcoming Investor Conferences in September
2026-09-02 12:00 · Yahoo
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year?
2026-08-11 13:40 · Yahoo
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-08-06 12:00 · Yahoo
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
2026-06-30 12:00 · Yahoo
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
2026-06-04 03:02 · Yahoo
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
2026-06-01 17:23 · Yahoo
Is ALX Oncology Holdings (ALXO) Outperforming Other Medical Stocks This Year?
2026-05-12 13:40 · Yahoo
ALX Oncology Q1 Earnings Call Highlights
2026-05-08 14:57 · Yahoo
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
2026-05-07 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.